Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

Vivos Therapeutics (Nasdaq: VVOS) reported that average weekly new obstructive sleep apnea patient referrals into its Nevada Sleep & Airway Medicine Centers rose 212% over the past six weeks compared with the prior six weeks.

Rhea-AI Summary

Vivos Therapeutics (Nasdaq: VVOS) reported that average weekly new obstructive sleep apnea patient referrals into its Nevada Sleep & Airway Medicine Centers rose 212% over the past six weeks compared with the prior six weeks. Since June 1, the total average weekly number of referrals has increased nearly five-fold and has continued to grow week over week.

The company will open an 8,100 sq. ft. sleep testing and treatment facility in Henderson, Nevada, on August 27, 2026. According to Vivos, the Henderson practice, previously in a smaller space, achieved its highest total collections in two of the past three months, and the company expects revenue from Henderson operations to grow further once the new facility is fully operational.

Positive

• 212% increase in average weekly new OSA patient referrals over six weeks
• Average weekly referrals nearly five-fold higher since June 1
• New 8,100 sq. ft. Henderson, Nevada sleep facility opening August 27, 2026
• Henderson practice recorded its highest total collections in two of the past three months

Negative

• None.

Argus Aug 25 session 19 alerts

-5.85% close to close 193.2x rel. volume Open Argus

Details

News Market Reaction – VVOS

+8.7% Peak Tracked

-11.6% Trough Tracked

$6.44M Market Cap

On Aug 25, the day this news came out, VVOS closed 5.85% below the previous close. Argus tracked a peak move of +8.7% during that session. Argus tracked a trough of -11.6% from its starting point during tracking. Our momentum scanner recorded 19 alerts for this stock that day. Relative volume reached 193.2x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 25 session.

Key Figures

Referral increase: 212% Comparison period: 6 weeks Average weekly referral growth: Nearly five-fold +5 more

Referral increase

212%

Most recent six-week period vs. prior six-week period

Comparison period

6 weeks

Most recent period compared with prior six weeks

Average weekly referral growth

Nearly five-fold

Since June 1

Facility opening

August 27, 2026

Henderson, Nevada facility

Facility size

8,100 sq. ft.

New Henderson sleep testing and treatment facility

Collections record

2 of the past 3 months

Highest total collections recorded by Henderson practice

Global affected population

One billion adults

Estimated adults aged 30–69 affected by OSA and insomnia

Undiagnosed share

80% or more

Affected adults estimated to remain undiagnosed and unaware

Historical Context

5 past events · Latest: Aug 20

5 events

1. Aug 20

   Facility opening

   24h Move

   +1.2%

   New Henderson facility announced to expand Nevada sleep testing and treatment capacity.

2. Aug 14

   Quarterly earnings

   24h Move

   -12.3%

   Second-quarter results showed revenue growth alongside larger losses and liquidity pressure.

3. Aug 14

   Earnings scheduling

   24h Move

   +12.4%

   Company scheduled second-quarter results release and investor conference call.

4. Aug 11

   AI partnership

   24h Move

   -0.9%

   Expanded Greenway Health engagement introduced AI-enabled clinical and revenue-cycle deployment.

5. Aug 05

   Patent issuance

   24h Move

   -26.3%

   Continuation patent broadened protection for Vivos CARE oral-device technology.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

obstructive sleep apnea, osa, 510(k) cleared, cpap

4 terms

obstructive sleep apnea medical

"patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

osa medical

"patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders"

Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.

510(k) cleared regulatory

"the only FDA 510(k) cleared technology for treating severe OSA in adults"

A 510(k) clearance is the U.S. Food and Drug Administration’s permission to market a medical device after the manufacturer shows it is sufficiently similar to one already legally sold. Think of it as getting a green light for a new product because it behaves like an approved model; it allows sales in the U.S. faster than a full approval and reduces regulatory risk, which can materially affect a company’s revenue prospects and valuation.

cpap medical

"legacy OSA treatments like CPAP are often mechanistic"

A CPAP (continuous positive airway pressure) device is a machine that gently blows a steady stream of air through a mask to keep a person’s breathing passages open during sleep, commonly used to treat sleep apnea. For investors, CPAPs matter because they represent a medical-device market with recurring sales of equipment and disposable supplies, subject to safety reviews, insurance reimbursement rules and regulatory approvals that can affect a maker’s revenue and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Average Weekly New Patient Referrals into Vivos’ Nevada Sleep & Airway Medicine Centers Rose 212% Over the Past Six Weeks from the Prior Six Weeks

LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week over week.

The Company recently announced the grand opening on August 27, 2026 of its new 8,100 sq. ft. state-of-the-art sleep testing and treatment facility in Henderson, Nevada. The Henderson practice previously operated within a limited physical space, yet in two of the past three months, it recorded its highest total collections to date. The Company expects revenue from its Henderson operations to grow further once the new facility becomes fully operational next week.

Vivos’ Chief Executive Officer, Kirk Huntsman, said, “We aggressively continue to refine and grow our Nevada operations and referral network. To that end, we recently made some significant operational and personnel changes which we believe will begin to pay dividends almost immediately. Having recently expanded our physical facilities and production capacity in that market, this growth in new patients at the top of our treatment and care funnel comes at a perfect time. We are well positioned and ready to process and care for these OSA patients, and expect to see important revenue growth to follow as these patients make their way through the system and we deliver care.”

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children. 

OSA and insomnia affect an estimated one billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward‑Looking Statements

This press release, including statements of the Company's management made in connection therewith, contains "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as "may," "would," "should," "expects," "projects," "potential," "intends," "plans," "believes," "anticipates," "hopes," "estimates," "goal," "aim," and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, statements regarding: recent patient referral trends at the Company’s Nevada Sleep & Airway Medicine Centers and their anticipated impact on the Company’s revenue; the expected continued growth of patient referrals; the expectation that patient referrals will convert to new Vivos patients resulting in increased revenue; the anticipated timing and benefits of the full opening of the Company’s new Henderson, Nevada facility; the anticipated effects of recent operational and personnel changes on the Company’s Nevada operations; the expected timing of any resulting revenue in the Company’s financial statements and its potential effect on the Company’s cash burn; and the potential impact of the foregoing on the Company’s competitive position, revenues, and overall growth.

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to: (i) the risk that recent increases in patient referrals may not continue or may not translate into increased revenue; (ii) the risk that the Company may be unable to recruit and retain the qualified medical, dental and clinical personnel needed to treat new patient referrals and increased demand; (iii) the risk that referral sources may reduce or discontinue referrals, or that the Company’s new Henderson, Nevada facility may not become fully operational when anticipated or may not generate the economic value the Company anticipates; (iv) risks associated with regulatory scrutiny of, and adverse publicity in, the sleep apnea and sleep disorder diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional financing to continue operations, acquire or affiliate with additional sleep center practices, or maintain its Nasdaq listing, when needed, if at all; (vi) market and other conditions that could impact Vivos' business or ability to obtain financing; and (vii) other risk factors described in Vivos' filings with the Securities and Exchange Commission (the "SEC"), which are available free of charge on the SEC's website at www.sec.gov.

Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vivos Therapeutics (VVOS) report about new patient referrals in Nevada on August 25, 2026?

Vivos Therapeutics reported a 212% rise in average weekly new OSA patient referrals into its Nevada centers. According to Vivos Therapeutics, this increase occurred over the most recent six-week period compared with the prior six weeks and has continued to grow week over week.

How much have Vivos Therapeutics’ Nevada referrals grown since June 1, 2026 (VVOS)?

Since June 1, Vivos Therapeutics’ total average weekly referrals in Nevada have risen nearly five-fold. According to Vivos Therapeutics, this growth in new patients has continued week over week, expanding the top of its treatment and care funnel at its Sleep & Airway Medicine Centers.

When will Vivos Therapeutics’ new Henderson, Nevada sleep facility open and how large is it (VVOS)?

The new Henderson, Nevada sleep testing and treatment facility is scheduled to open on August 27, 2026 and is 8,100 sq. ft. According to Vivos Therapeutics, this practice previously operated in a limited space, and the expanded facility increases its treatment and production capacity.

What revenue trends has Vivos Therapeutics reported at its Henderson, Nevada practice (VVOS)?

Vivos Therapeutics reported that its Henderson practice recorded its highest total collections in two of the past three months. According to Vivos Therapeutics, it expects revenue from Henderson operations to grow further once the new 8,100 sq. ft. facility becomes fully operational next week.

How might higher Nevada referrals impact future revenue for Vivos Therapeutics (VVOS)?

Increased referrals may support future revenue growth as more patients move through the care system. According to Vivos Therapeutics, it is well positioned with expanded Nevada facilities and expects important revenue growth as these obstructive sleep apnea patients receive testing and treatment over time.

What services does Vivos Therapeutics focus on for obstructive sleep apnea patients (VVOS)?

Vivos Therapeutics focuses on diagnostic and treatment methods for obstructive sleep apnea and related sleep disorders. According to Vivos Therapeutics, its FDA-cleared CARE oral medical devices and Vivos Method are designed to address anatomical factors linked to OSA in adults and children.